Tirzepatide and semaglutide are both GLP-1 medications used for medical weight loss, but they aren’t interchangeable. Tirzepatide is a dual-receptor medication that activates both GLP-1 and GIP pathways and produces average weight loss of about 21% of body weight. Semaglutide activates only GLP-1 and produces average weight loss of about 15%. Tirzepatide tends to be the right choice for patients with 60 or more pounds to lose or significant insulin resistance. Semaglutide is the right starting point for patients newer to GLP-1 therapy or losing under 60 pounds. Both medications are prepared at InfusaLounge by licensed, FDA-registered 503A and 503B compounding pharmacies under the medical oversight of Phyllis J. Gee, MD, FACOG.
Three years ago, the decision wasn’t this complicated. Semaglutide had just opened up access to medical weight loss, and the conversation in our Allen consultation room was about whether to start. Now patients walk in already knowing the names — tirzepatide and semaglutide — and the question has changed. It’s no longer whether. It’s which one.
There’s no universal right answer. There’s a right answer for you, based on how much you have to lose, how your body responds to medication, how much insulin resistance you’re carrying, and what you can sustain long-term. The way Triny Nguyen, APRN walks every new patient at InfusaLounge through this decision is exactly what I’m going to walk you through here.
What Both Medications Actually Do
Before you can compare them, it helps to understand what they have in common. Semaglutide and tirzepatide both belong to a class of medications called GLP-1 receptor agonists. They mimic a hormone your gut releases after meals — a hormone that signals fullness to your brain, slows the rate at which food leaves your stomach, and helps your pancreas manage blood sugar.
In plain terms, they make you less hungry, more easily full, and more metabolically efficient. They do not burn fat. What they do is change your relationship with food in a way that finally makes a caloric deficit feel manageable, often for the first time in years.
That distinction matters because it shapes what kind of result you should expect. According to the National Institute of Diabetes and Digestive and Kidney Diseases, obesity affects more than 40% of American adults and is associated with type 2 diabetes, cardiovascular disease, and other serious conditions. GLP-1 medications represent one of the most significant advances in obesity treatment in decades — not because they’re a shortcut, but because they make the long, hard work of weight loss biologically possible for people whose bodies have been fighting against it.
The Core Difference: One Receptor vs. Two
Here’s where the two medications diverge. Semaglutide activates one receptor: GLP-1. Tirzepatide activates two: GLP-1 and GIP. That second receptor — GIP, short for glucose-dependent insulinotropic polypeptide — is a metabolic accelerator that supports insulin response, fat metabolism, and appetite regulation through an entirely separate pathway.
This is the reason head-to-head trials consistently show greater average weight loss with tirzepatide than with semaglutide. Tirzepatide doesn’t just turn down your appetite the way semaglutide does. It hits a second metabolic switch at the same time. Semaglutide adjusts one dial. Tirzepatide adjusts two.
What the Research Shows
The numbers tell the story most clearly. The pivotal SURMOUNT and STEP clinical trial programs established the baseline results most providers reference today, and the difference between the two medications is consistent across studies.
For semaglutide, the STEP 1 trial published in the New England Journal of Medicine showed average weight loss of approximately 15% of body weight at 68 weeks. For tirzepatide, the SURMOUNT-1 trial published in NEJM showed average weight loss of approximately 21% of body weight at 72 weeks at the highest dose.
What does that look like in real terms? For someone starting at 220 pounds, semaglutide produces an average loss of about 33 pounds. Tirzepatide produces an average loss of about 46 pounds. Both are clinically significant. Tirzepatide is the more aggressive option, and for patients with substantial weight to lose, that 13-pound difference compounds into a meaningfully different outcome.
What Are the Side Effects of Tirzepatide and Semaglutide?
For all the differences in mechanism, the side effect profiles of these two medications look remarkably alike. Both are dominated by gastrointestinal symptoms — nausea, constipation, occasional vomiting, and reflux are the common complaints, particularly during the first few weeks and after dose increases. The good news, and Triny tells every new patient this in consultation, is that these symptoms almost always fade as your body adapts.
The way side effects get managed at InfusaLounge is straightforward. Triny titrates doses slowly. Hydration gets supported aggressively, often with an IV during the first few adjustment weeks. Every patient has direct phone access to Triny if anything feels off. Most side effect problems are titration problems in disguise. Slow it down and the symptoms generally take care of themselves.
The rarer but more serious risks — pancreatitis, gallbladder issues, thyroid concerns — are the same for both medications. The FDA prescribing information for semaglutide and tirzepatide details these warnings in full. Triny screens carefully before starting any protocol, with Dr. Gee providing medical oversight, and monitors patients through the first three months and beyond.
Cost Considerations in 2026
Cost is the conversation Triny has most often in consultation, because the financial picture has shifted significantly over the past year. At InfusaLounge, both medications are prepared by licensed, FDA-registered 503A and 503B compounding pharmacies.
Pricing and availability change frequently, sometimes month to month. Rather than publishing numbers that may be out of date by the time you read them, Triny walks every patient through current pathways and costs transparently during consultation. Call us at 972-546-4318 for current options.
When Semaglutide Is the Right Choice
With the mechanics and the numbers in mind, here’s how Triny thinks about the choice in consultation. Semaglutide is generally the right starting point for patients newer to GLP-1 therapy or with under 60 pounds to lose. It tends to be more affordable than tirzepatide, has a more moderate intensity, and serves as a strong entry point for sustainable progress.
It’s likely your starting point if you’re new to GLP-1 therapy and want to ease in, if you’re looking to lose 30 to 60 pounds, if you tend to be more sensitive to medications in general and want the lower-intensity option, if cost is a primary factor, or if you’re closer to your goal weight already and want steady, sustainable progress rather than maximum velocity.
When Tirzepatide Is the Right Choice
Tirzepatide is often the better fit for patients with 60 or more pounds to lose, significant insulin resistance, or those who have plateaued on semaglutide. The dual-receptor mechanism provides more aggressive metabolic intervention for patients who need it.
You’re probably looking at tirzepatide if you’re trying to lose more than 60 pounds, if you’re struggling with significant insulin resistance or metabolic syndrome, if you’ve tried semaglutide before and plateaued, if you want the most aggressive evidence-based option, or if you have stubborn visceral fat that hasn’t responded to lifestyle changes alone.
How to Start at InfusaLounge in Allen
The process from your first call to your first injection typically takes about a week. Triny handles the consultation and ongoing clinical management. Dr. Gee provides medical oversight on every protocol.
It starts with a consultation, either in person at our Allen clinic or by secure video. Triny will review your medical history, current medications, weight loss goals, and any prior GLP-1 history. That conversation takes about 30 minutes. Most patients can start without extensive labs, though Triny will sometimes order targeted bloodwork based on what you tell her. Together, you and Triny will choose semaglutide or tirzepatide and you’ll begin at the lowest effective dose to minimize side effects.
Most patients start their first injection within a week of their consultation. We’ll train you on self-injection at home, or schedule weekly clinic visits if you prefer that route. From there, monthly check-ins, dose adjustments as needed, and direct phone access to Triny if you have questions between visits.
Frequently Asked Questions
Can I lose weight with GLP-1 therapy if I have only 20 to 30 pounds to lose?
Yes, though many patients in this range do well on a lower-dose semaglutide protocol with a planned exit strategy rather than long-term use. Triny will discuss whether GLP-1 therapy is the right tool for your specific goals during consultation.
Will I gain the weight back when I stop?
Some patients do, particularly if they stop without a transition plan. A 2022 study published in Diabetes, Obesity and Metabolism found that patients who stopped semaglutide regained about two-thirds of their lost weight within one year. This is why Triny builds a maintenance strategy with every patient before they’re done losing.
Can I combine GLP-1 therapy with other InfusaLounge therapies?
Yes. Many of our weight loss patients also do regular B12 injections for energy, NAD+ infusions during plateaus, and IV hydration when side effects flare. We coordinate all of it under one roof.
Is GLP-1 therapy safe long-term?
The molecules themselves have been FDA-approved for type 2 diabetes for years and for weight loss since 2021 (semaglutide) and 2023 (tirzepatide). Long-term safety data continues to accumulate and is reassuring for properly monitored use. We require regular check-ins precisely so that monitoring happens.
Do I have to come into the Allen clinic to start tirzepatide or semaglutide?
No. Initial consultations can be in person at our Allen clinic or by secure video with Triny. After the consultation, most semaglutide and tirzepatide patients self-administer at home with our guidance.
Ready to Start?
If you’ve been wondering which GLP-1 is right for you, the most useful thing you can do is stop reading and book a consultation. Triny will walk you through the decision in less time than it took you to read this article — and you’ll leave with a clear plan, an honest cost expectation, and a specific path forward.
InfusaLounge Integrative & Functional Medicine
190 E Stacy Rd #1720, Allen, TX 75002
Call 972-546-4318 or book online
Serving Allen, McKinney, Frisco, Plano, and surrounding North Dallas communities.
About the Authors
Medically reviewed by Phyllis J. Gee, MD, FACOG. Dr. Phyllis J. Gee is Medical Director of InfusaLounge Integrative & Functional Medicine. A board-certified OB/GYN and Fellow of the American College of Obstetricians and Gynecologists, she completed her Bachelor of Science in Nutrition at Cornell University, her MD at Wayne State University School of Medicine, and her residency in Obstetrics and Gynecology at Albert Einstein College of Medicine. She is an ADAPT-trained Functional Medicine practitioner (Kresser Institute) with more than 30 years of clinical experience. Dr. Gee’s research on transcervical fibroid ablation has been published in the International Journal of Gynecology and Obstetrics, and she served as a site investigator in the FDA-reviewed SONATA Pivotal IDE clinical trial. She has been cited in The New York Times. NPI 1417953241 · Texas Medical License H1583. View full bio →
Written by Melissa Chester, BBA. Founder and Director of Operations, InfusaLounge Integrative & Functional Medicine. Healthcare operations leader who built InfusaLounge from the ground up in 2018, with direct operational oversight of every clinical program. View full bio →
